Every guide.

HGH fragment 177-191. Phase IIb obesity trial NEGATIVE — honest framing, FDA GRAS for food not drug approval.

Pro-apoptotic peptide targeting adipose vasculature. Phase I kidney toxicity halted development — honest safety framing.

Long-acting amylin analog. 9.7% body-weight reduction in Phase 2 monotherapy; 20.4% for CagriSema in REDEFINE-1.

An engineered oxyntomodulin analog approved in China — the most biomimetic design in the class, and the lowest dual-agonist result.

Complete research guide — triple GIP/GLP-1/glucagon agonist: the Phase II readout that reset the upper bound of pharmacological body-weight reduction.

The dual agonist that picked glucagon instead of GIP — ~19% in Phase 2, and a liver program that may matter more than the obesity one.

Complete research guide — FDA-approved dual GIP/GLP-1 agonist: SURMOUNT, SURPASS, and the field-defining body-weight endpoint curves.

What the adipotide studies administered — 0.43 mg/kg daily in obese macaques, a 0.03 mg/kg Phase 1 starting dose…

Six compounds ranked two ways — by trial magnitude and by evidence quality — and why those two orderings disagree.

Cagrilintide + semaglutide fixed-dose combination. 20.4% mean body-weight reduction at 68 weeks — the largest pharmacological figure documented.

Photos labeled cagrilintide usually show CagriSema. Cagrilintide alone cut body weight 9.7% over 26 weeks in its Phase 2 trial.

Most cagrilintide benefit claims quote 20.4%. That number belongs to CagriSema. Cagrilintide alone cut weight 9.7% in a 26-week Phase 2 trial.

Cagrilintide's side effect record is mostly gastrointestinal, mostly from CagriSema trials, and it stops at 68 weeks. There is no FDA label yet.

Semaglutide, tirzepatide, retatrutide, mazdutide, cagrisema. The current state of the class, by trial readout.

How the GLP-1 receptor agonists got from exendin-4 to triple agonists — and where the class is going next.

A Phase 3 trial site or the research-chemical market. There is no prescription route, no compounding route, and no telehealth route.

No — not anywhere. Where the TRIUMPH Phase 3 program stands, what it has to establish, and why an unapproved compound is sold openly.

24.2% body-weight reduction at 48 weeks (NEJM 2023). The setup for the Phase III readouts in progress.

The honest version is a distribution, not a photograph: −24.2% mean at 12 mg, 83% losing 15%+, and the one in six who did not.

Retatrutide's 24.2% weight loss is real Phase 2 data in 338 adults. The heart, kidney and sleep-apnea benefits come from other drugs' trials.

The published Phase 2 protocol — 1/4/8/12 mg targets, 2–4 mg starting doses, 12-week escalation — and why there is no approved dose.

Class-typical gut effects plus the dose-dependent heart-rate rise peaking at week 24 — and what 338 people over 48 weeks cannot detect.

GIP + GLP-1 + glucagon receptor engagement. Why adding the glucagon arm changes the energy-balance math.

Two pharmaceutical heavyweights compared. Where the dose-response curves diverge.

NEJM 2022 Phase III in obesity — 22.5% mean body weight reduction at 72 weeks, the highest pharmaceutical figure on record.

STEP-1's four-step, 16-week climb from 0.25 mg to 2.4 mg — and the cardiovascular outcome data no other compound in the class has.

SURMOUNT-1 measured 22.5% mean weight loss over 72 weeks. The photos don't show the titration, the placebo arm, or the regain after stopping.

The SURMOUNT-1 escalation — 2.5 mg start, 2.5 mg steps every four weeks — and the estimand difference behind 20.9% versus 22.5%.

How a single 39-residue peptide engages two incretin receptors — and why the GIP arm changes the outcome.

Indication, dosing schedule, GI tolerability, and where the compounded vs. branded distinction matters.

In SURMOUNT-1, 33% reported nausea, 22% diarrhea, 12% vomiting. Most were mild. What the record still lacks: tirzepatide heart-outcome data.

SURMOUNT-5 head-to-head — tirzepatide outperformed semaglutide on body-weight reduction with comparable adverse-event profile.

No retail price exists for an unapproved drug. How to normalize research-vial pricing to cost per mg, and why the cheapest sticker rarely is.

A 2026 sourcing guide for AOD-9604 (hGH fragment 176-191)

A 2026 sourcing guide for semaglutide as a research reference compound

2026 sourcing guide for the triple-agonist landmark — pre-approval framing, the FG-series codename problem, pricing, and the CoA red flags.

Sourcing tirzepatide for research — the 3 channels (prescription / 503A / RUO), pricing across them, and the identity-verification questions.

Complete research guide — identity, multifactorial mechanism, the 35:1 preclinical-to-human ratio, FDA Cat 2 / WADA S0 status.

Complete research guide — thymosin-β4 (1-43 fragment), actin binding, cell migration, and the cardiac-repair preclinical signal.

VEGF-driven angiogenesis (BPC-157) + actin-monomer-driven cell migration (TB-500). Where the mechanisms converge.

20 mg at 1:1 — one draw delivers both, so the calculation has to be run twice.

How a 15-residue peptide upregulates VEGFR2 expression and triggers tube formation in endothelial cell assays.

Where the gut-healing claim actually comes from — VEGF, NO synthase, and dose-response in rodent colitis models.

No study has ever measured a BPC-157 before and after. The whole human record is three uncontrolled pilot reports…

36 studies, 35 of them in animals, roughly 80% from one research group. What's claimed, what's behind each claim, and why the mechanism makes the breadth plausible.

10 mg vial to syringe units, and the microgram mistake that costs a factor of a thousand.

No human dose-finding trial has ever been run. Why the animal doses do not convert, and why every online chart agrees with every other.

Reconstitution, half-life, route of administration, and what the literature does and doesn’t say about safety.

Retrospective chart review of 16 patients with intra-articular BPC-157 — phone-recall outcomes only, no controls.

No controlled human safety data exists — three small uncontrolled reports is the entire record. What the animal work shows and what the FDA concluded.

Two different molecules for two different problems. When the literature supports stacking, and when it doesn’t.

First systematic review of 36 studies on BPC-157 for orthopaedic indications. Honest about the human-evidence gap.

The peptides most-studied for joint health, ranked by published evidence — and the standard-of-care context they're usually compared against.

An honest review of the strongest recovery peptides, anchored to peer-reviewed evidence rather than marketing.

BPC-157 survives human gastric juice for over 24 hours, so rats were dosed in drinking water. What those studies…

The G-actin sequestration model — how Tβ4 controls the actin monomer pool and modulates cell motility.

Almost every TB-500 benefit traces back to thymosin beta-4 research in animals and cells. Human trials of TB-500 itself number zero.

Murine MI models show Tβ4-driven epicardial reactivation. Human Phase II hit the primary endpoint; Phase III is pending.

10 mg vial to syringe units, and the identity problem the arithmetic sits on top of.

TB-500 has zero human trials, so its side effects have never been measured. Here is what the safety record…

The most-stacked combination in research peptides. What the additive-mechanism case looks like and where it falls apart.

BPC-157 + TB-500 — the most-named peptide stack in the research community. Where the name came from, the mechanism, and what the evidence supports.

BPC-157, TB-500, and the BPC/TB blend. The class-level evidence picture and how the molecules differ.

Research sourcing guide — CAS 137525-51-0, the 503A Category 2 framing, real pricing benchmarks, and the BPC-specific red flags.

A 2026 sourcing guide for the pre-mixed BPC-157 + TB-500 blend

Complete research guide — two molecules share the name: DAC vs. no-DAC half-life, the receptor pharmacology, and the missing human trials.

Synthetic GnRH decapeptide. Factrel discontinued; pulsatile-vs-continuous pharmacology, TRT-adjunct off-label.

GHRP family — high GH-release potency, tachyphylaxis limitation, cardiac-protection preclinical signal.

Long R3 IGF-1 with N-terminal extension. Extended half-life, reduced IGFBP binding — honest cancer-biology framing.

Complete research guide — the selective ghrelin-receptor agonist: the GH peptide that doesn’t spike cortisol or prolactin.

GHRH 1-29 analog — the 29-aa original used as Geref through 2008. Mechanism, evidence, and modern half-life context.

Complete research guide — FDA-approved stabilized GHRH analog, the gold standard for the class.

The rare research peptide with a real controlled result. A 24-week placebo-controlled trial in about 500 people found no benefit.

What the AOD-9604 trials administered — 25 to 400 mcg/kg intravenously, then oral doses from 54 mg down to 0.25 mg…

The growth-hormone axis ranked by evidence rather than reputation — and the hypertrophy outcome studies that mostly do not exist.

10 mg at 5 mg each, dosed in micrograms. Two conversions in one calculation.

The published evidence on the CJC + ipamorelin combination — what’s actually been tested vs. claimed.

How a GHRH analog with a maleimidopropionyl modification ends up albumin-bound with an 8-day half-life.

No trial has ever dosed CJC-1295 and ipamorelin together. What each was given at separately, and why the DAC…

The only controlled CJC-1295 data measured blood, not bodies. Two 2006 trials ran 28 and 49 days. No DEXA, no weight, no photographs.

CJC-1295's only measured benefit is a blood number. GH rose 2- to 10-fold in two 2006 trials. Fat, muscle and…

Two small 2006 trials are the entire human safety record for CJC-1295. They report no serious reactions over 28 to…

Different receptors, different pulse patterns. Why the "stack" became the dominant grey-market combination.

Both are stabilized GHRH analogs. Why one is FDA-approved and the other isn’t.

Tesamorelin (FDA-approved), CJC-1295, ipamorelin, sermorelin, hexarelin. The full landscape, in tiers.

CJC-1295 + Ipamorelin + Tesamorelin — supra-additive GH release across GHRH + GHRP receptors. Why athletes stack all three.

Hexarelin's human doses were 0.5 to 2 mcg/kg, oral bioavailability was 0.3%, and the one 16-week study watched the…

Growth hormone secretagogue receptor pharmacology — why ipamorelin is more selective than GHRP-2 or hexarelin.

It reached Phase III and missed its endpoint. Zero randomized trials cover muscle, fat, aging or recovery.

Ipamorelin has been given to humans in one published trial, at 0.03 mg/kg into a vein. What that trial found, and…

All three release growth hormone — the literature separates them on cortisol, prolactin and hunger.

The honest before-and-after is a blood test, not a photo: IGF-1 restored to the young-adult range in 14 days in 1990s trials — and zero modern RCTs behind the transformation claims.

Vial to syringe units, and why very small draws are the accuracy problem on this compound.

Sermorelin's side effect list comes from a label pulled in 2008, not a trial. The longest controlled dosing study ran 16 weeks. Zero RCTs since 2020.

Tesamorelin cut visceral fat 15.2% in 26 weeks against a 5.0% gain on placebo. The measured before and after, the…

Tesamorelin has real trial data for one thing: visceral fat in HIV lipodystrophy. Liver fat and immune markers follow. Cognition missed in 2025.

Pilot-stage trials in MCI and mild Alzheimer’s — directional cognitive signal, no Phase III evidence yet.

The rare compound here with a labeled dose rather than a reconstruction — and two correct numbers that cause most of the confusion.

5 mg vial to concentration, draw volume and U-100 units, with the 2 mg trial dose to check the arithmetic against.

The pivotal RCTs that earned FDA approval — VAT reduction, IGF-1 dynamics, and the long-term safety extension data.

The only compound in this class where side effects were measured rather than guessed. The glucose effect is the one with clinical weight.

DPP-4 resistance and the structural changes that turn a 30-minute peptide into a once-daily injectable.

The stabilized FDA-approved GHRH analog vs the discontinued original fragment — mechanism, half-life, evidence depth, regulatory status, and cost, compared honestly.

Ipamorelin sourcing — the Aib residue identity check, selectivity-vs-cost logic, and the CJC-1295 stack context.

Discontinued commercially, not for safety — which leaves two routes. Why degradation matters more than identity for this one.

Three channels: Egrifta prescription, 503A compounded, third-party tested RUO. Mass-spec on the trans-3-hexenoyl modified peptide.

Complete research guide — selective NNMT inhibitor: the murine adipose-tissue signal, the mechanism, and the absent human trials.

AED tripeptide for cartilage research. Khavinson cytogen — preclinical-strong, RCT-poor.

Complete research guide — Russian tetrapeptide aging program: Khavinson’s 1971 work, the telomerase claims, and the methodological gaps Western labs flagged.

Complete research guide — 16-residue mitochondrial-encoded peptide: the "exercise mimetic" claim, the AMPK story, and the human-trial gap.

Complete research guide — IV infusion, NMN, NR, NAM: the four ways to address declining cellular NAD+ and what the data actually supports.

EDR tripeptide, Khavinson school. Russian preclinical work, mitochondrial proposals, thin Western RCT base.

Complete research guide — mitochondria-targeted tetrapeptide, FDA-approved for Barth syndrome (Forzinity, Sept 2025).

KED tripeptide, Khavinson cytogen for vascular research. Thin Western RCT data.

Nicotinamide N-methyltransferase inhibition shifts the methyl-donor balance. The energy-expenditure case.

High-fat-fed mouse models show body-weight reduction without locomotor change. Sample size, dose, and translation limits.

Zero human trials have ever run. The striking rodent result also changed the diet, so the diet is inside the finding.

Fat loss, NAD+, muscle, longevity. We trace each 5-Amino-1MQ benefit claim to the study behind it. Most land in mice or cells. Human trials: zero.

What the 5-amino-1MQ studies administered — 20 mg/kg three times daily under the skin in mice — and why the…

5-Amino-1MQ has zero published human trials, so no human side effect record exists. What exists is 11 days of mouse dosing and mechanism theory.

An honest review of the most-cited anti-aging peptides, anchored to peer-reviewed evidence rather than longevity marketing.

A 2025 first-in-class approval for Barth syndrome, genotype-dependent myopathy results, and preclinical aging work — one cardiolipin mechanism throughout.

Multi-decade Russian elderly-cohort trials. Survival, T-cell parameters, and the methodological limits of the data.

No randomized human trial of Epithalon exists. What the studies used — 0.05 mcg/mL in culture, 1 mcg per mouse…

The pineal-telomerase upregulation hypothesis. What’s replicated, what isn’t, and what stays unfalsifiable.

How a 16-residue ORF-encoded peptide activates AMPK and modulates the AICAR pathway in muscle.

Murine models show insulin sensitization without exercise. The human-extrapolation problem.

Zero randomized trials of injected MOTS-c exist. Every human number is observational, and a correlation is not a before and after.

MOTS-c activates AMPK and rises with exercise, which is where the exercise-mimetic framing comes from. What the…

No human trial has established a MOTS-c dose. The exact doses the mouse studies used, why mg/kg does not convert…

No published trial has ever given MOTS-c to a person, so no side effect has been measured. Any list with…

SS-31, MOTS-c, humanin, and the ORF-encoded peptide class. The state of the field as of 2026.

SIRT1-7 deacetylase dependence on NAD+. The mechanism that anchors most of the popular longevity-market claims for the molecule.

Four RCTs of oral NMN found small gains in walking speed and grip strength. The IV drips have no randomized support for what they claim.

The NAD+ safety record is four short trials of oral NMN and NR in about 230 adults. The IV drip sold in clinics has no randomized safety data.

IV NAD+, NMN, NR, NAM. Bioavailability, tissue distribution, and where the head-to-head trials land.

Accelerated approval based on the pivotal TAZPOWER + extension data. The first disease-specific therapy for Barth.

Selective binding to cardiolipin in the inner mitochondrial membrane — how it preserves cristae structure and ETC efficiency.

Two mitochondrial peptides with different mechanisms. Where the use-cases overlap and where they diverge.

SS-31 + MOTS-c + NAD+ — three complementary mitochondrial mechanisms. Zero published controlled human trials of the combination.

Mitochondrial-derived 16-aa peptide. 12S rRNA identity check, the exercise-mimetic marketing-vs-evidence gap.

Acetyl Hexapeptide-3 — the "Botox-like" SNAP-25 inhibitor. Topical anti-wrinkle evidence and cosmeceutical regulatory framing.

Complete research guide — endogenous copper tripeptide that declines with age, with the strongest topical signal in the catalog.

BPC-157 + TB-500 + GHK-Cu in one 70 mg vial. Per-constituent mechanism and evidence — and the honest gap: zero trials on the combined stack.

Complete research guide — the master endogenous antioxidant: redox cycling, IV vs. oral controversy, and the skin-lightening evidence base.

Palmitoyl Pentapeptide-4 (KTTKS). Topical collagen-stimulating cosmeceutical with dermatology RCT base.

The peptides most-studied for hair growth, ranked by published evidence — and honestly compared to minoxidil and finasteride.

An honest review of the strongest skin-health peptides, anchored to where the published evidence actually supports each route of administration.

Carrier choice matters. How tallow, ceramide, and aqueous bases change the GHK-Cu delivery profile.

Type I/III procollagen mRNA upregulation in dermal fibroblasts. The biochemical case in dermal-aging (photoaging) research.

Anagen-phase prolongation in hair-pluck cultures. The case for and against scalp injections vs. topicals.

Topical GHK-Cu has 12-week controlled cosmetic data in 71 women. Injectable GHK-Cu has no human trial at all. The…

Most GHK-Cu benefit claims trace to topical creams, copper chemistry, or mouse studies. Here is which is which, and what injections have.

RCTs on GHK-Cu topical creams in photoaged skin — wrinkle depth, hydration, elasticity. Effect sizes and study limits.

Two routes, two evidence bases. Topical has studied concentrations; injectable has zero human RCTs and a copper-load question nobody has looked at.

Topical GHK-Cu has about 30 controlled studies and mostly skin complaints. Injectable GHK-Cu has zero published human trials, so no safety record.

Diabetic ulcer and burn-wound trials. Where the topical formulation reaches and where systemic injection adds nothing.

The route-of-administration debate. Why topical formulations dominate the published literature.

The controlled evidence is a 46-person, 8-week topical and oral trial. The IV route in the photos carries FDA warnings and reported deaths.

Published glutathione doses — 250 to 1,000 mg daily by mouth, 600 to 1,400 mg intravenously — and why the trials…

GSH/GSSG ratio, glutathione peroxidase, and why "supplementing antioxidants" isn’t the same as raising cellular GSH.

Oral glutathione's side effect record is one 46-person, 8-week trial. The IV route carries FDA warnings citing Stevens-Johnson syndrome and deaths.

A class of trials with positive descriptive findings but persistent methodological holes — and an FDA warning letter on IV use.

The class-level landscape. Where the topical evidence is real (GHK-Cu) and where it isn’t (most else).

GHK-Cu sourcing — copper-complexed vs uncomplexed identity, blue-powder check, topical vs injectable evidence, and pricing.

A 2026 sourcing guide for the GLOW Blend

Pre-mixed 80 mg vial or GLOW plus KPV assembled from two — what each route costs, and the four checks a blend certificate must survive.

Complete research guide — the DSIP nonapeptide: 1977 isolation, the sleep-architecture literature, and the trial-quality gap.

Complete research guide — FDA-approved melanocortin agonist for HSDD: Vyleesi, the Phase III data, and the off-label dose-response.

Complete research guide — Russian heptapeptide derived from tuftsin: GABAergic modulation, anti-anxiety claims, and the trial-quality picture.

Complete research guide — Russian heptapeptide derived from ACTH(4-10): BDNF upregulation and the stroke-recovery indication.

The peptides most-studied for cognition, ranked by published evidence — including Cerebrolysin's negative 2023 Cochrane finding.

The peptides most-studied for sexual health, ranked by published evidence — and honest about PT-141's 40% nausea rate and Melanotan II's melanoma concerns.

An honest review of the most-marketed sleep peptides, with explicit framing on where the published evidence supports the claims and where it doesn’t.

The slow-wave-sleep induction hypothesis — what the EEG data actually shows and where it doesn’t replicate.

Marketed DSIP benefits trace to a 1977 rabbit paper, one 1988 cortisol report, and rat stroke work. No human sleep trial confirms the name.

Cortisol-suppression trials in chronic stress cohorts. Endpoint definitions, sample sizes, and study limits.

An approved melanocortin drug with a debated effect size against a hypothalamic hormone with early controlled trials.

A history of Russian neuropeptide research — tuftsin, ACTH(4-10), and the molecules that didn’t cross the Western methodological bar.

The pivotal Phase III RECONNECT and PRISM studies — efficacy magnitude, adverse-event profile, and the FDA approval.

MC4R activation in the hypothalamus — the neural mechanism behind the sexual-arousal effect.

Vial to syringe units, anchored to the 1.75 mg dose on the approved Vyleesi label.

PT-141 is the rare peptide with an approved human dose: 1.75 mg by autoinjector. The label's numbers, its limits…

Bremelanotide was developed as a nasal spray first. Blood-pressure rises and erratic uptake killed that route, and…

Nausea hit 40% in the bremelanotide trials. About 18% quit over side effects. Skin darkening, blood pressure, and what was never tested.

Russian heptapeptide pair — two neuropeptide classes. Institute of Molecular Genetics provenance, honest Western RCT framing.

Russian GAD trials — symptom-scale response in 60–80% of cohorts, but limited blinding and small sample sizes.

Selank's only Western human data is a 2020 fMRI study in 52 healthy adults. Western randomized trials: zero. Here is what was actually measured.

Selank's benefits, split by evidence: one fMRI study in 52 adults, rat stress work, and Russian trials you cannot…

Russia registered Selank as 0.15% nasal drops. The anxiety trials everyone cites for it published no dose at all…

Intranasal is Selank's registered clinical route in Russia, unlike most peptides sold as sprays. What the Russian…

How a stabilized tuftsin analog modulates GABA-A receptor expression and reduces anxiety-related behavior in models.

Both Russian-school neuropeptides. Different parent peptides, different receptor targets, different use-cases.

The ACTH(4-10)Pro-Gly-Pro structure and how it engages BDNF signaling without the corticotropic side-effects of full ACTH.

The only human before and after for Semax is a 2020 brain scan of 52 healthy adults. No Western randomized trials. Everything else was measured in rat

Semax benefits are almost all rat data. One human imaging study in 52 adults, zero Western RCTs. Which study sits…

What the published Semax studies administered — 12 and 18 mg a day in the 1997 stroke report, and the two…

Semax has one published human study: 52 healthy adults scanned in 2020. No adverse event table. The side effect list you read online has no source.

Russian post-stroke trials show motor-function improvement. Methodological details and the Western-replication gap.

DSIP, semax, selank, ipamorelin. Where the sleep-architecture claims have data and where they don’t.

Complete research guide — the C-terminal tripeptide of α-MSH: melanocortin signaling, the cleanest preclinical signal for ulcerative colitis.

KEDG tetrapeptide, Khavinson school. Proposed thymic function support; single-source-dominance flagged.

28-aa Zadaxin/Thymalfasin. 35+ country approval, FDA-unapproved in US. 2025 BMJ TESTS Phase III sepsis negative.

KE dipeptide, Khavinson cytogen for immune cell proliferation. Honest evidence-base framing.

An honest review of the most-cited gut-health peptides, anchored to peer-reviewed preclinical evidence for GI indications.

The peptides most-studied for immune support, ranked by published evidence — including the negative 2025 TESTS Phase III sepsis trial on Thymosin Alpha 1.

No human KPV trial has been published. What the colitis studies administered — 10 nM in culture, 100 µM in mouse…

DSS-induced colitis models, oral and topical formulations, and the dose-response. Human trials still pending.

MC1R-independent anti-inflammatory action. Why a 3-residue peptide retains the parent molecule’s function.

An elegant mechanism and the largest gap between marketing and published human evidence of anything in this library.

Approved abroad as thymalfasin, unapproved at home, and at the center of FDA's 2026 compounding docket.

Every verified thymosin alpha-1 trial used 1.6 mg subcutaneously — twice weekly for hepatitis, twice daily for…

Four compounds in one 80 mg vial — GHK-Cu, BPC-157, TB-500 and KPV. What is in it, and what the combination has behind it.

Identity before purity, the lab before the number, and the lot match that makes a certificate apply to the vial in your hand.

The published legal position — RUO under 21 CFR §809.10, what “not for human consumption” means, 503A categories, WADA, and buying vs selling vs administering.

Why 0.9% benzyl alcohol is the standard diluent for peptide vials — and what the sterile-water and saline alternatives actually do.

The peptides with the lowest entry barriers for new researchers — ranked by safety, ease of use, and evidence depth.

USA-specific buyer's guide — state legality, customs framework, FDA RUO labeling, payment processors, and shipping logistics.

Two documents, two purposes. The Certificate of Analysis grades the product; the Safety Data Sheet covers handling.

Most raw material is synthesized in China, including what Western brands relabel. What buying direct actually changes — and what it doesn't.

What a melted gel pack proves, what the accelerated stability arm is for, and why the published heat data belongs to other molecules.

Controlled trials of the blend number zero. The nearest human data is a phone survey of 16 knee patients given one of its three compounds.

GLOW is BPC-157, TB-500 and GHK-Cu in one vial. Each has its own literature. The combination has none, and that…

No study has given BPC-157, TB-500 and GHK-Cu together. What each was administered at separately, and why a fixed…

HPLC measures purity. LC-MS establishes identity. What each test proves, what a certificate has to report for both, and why one number is not enough.

Subcutaneous, IM and IV compared — why the gut destroys peptides, and why insulin-syringe units measure volume rather than dose.

Solid-phase peptide synthesis — the Merrifield method, coupling chemistry, and why HPLC purity matters for the final product.

Receptor binding, signal cascades, and the difference between peptide hormones and structural peptides.

A 2026 buyer's guide — the eight criteria, real price-per-mg ranges by class, the regulatory framing, and a 30-minute vendor verification checklist.

Identity, purity, endotoxin, microbial, heavy metals. The six tests on every COA — and what the numbers actually mean.

Why diluent goes down the vial wall, why swirling beats shaking, and how long a peptide lasts once it is in solution.

The checks that work from outside: the certificate, the named lab, the accreditation lookup, the six questions to ask, and what each red flag means.

The international standard for testing-lab competence. Why accredited labs carry it, and what it changes about COA credibility.

NAD+ is a dinucleotide, not a peptide — it has no amino acids and no peptide bonds. Why it is sold beside…

80 mg at 50/10/10/10 — one draw, four compounds, and a copper ceiling.

Nothing has been measured for the four-compound blend. Half the vial has no human trial at all, and four fixed variables make attribution impossible.

A KLOW benefits list is four separate literatures under one label. Each claim taken back to the ingredient it came from.

No study has given the four compounds together. What each was given separately, and the 80 mg reconstitution arithmetic.

No safety study of the blend exists, two components have no human data at all, and the vial carries roughly 7.9 mg of copper.

GLOW is 70 mg of three compounds. KLOW adds 10 mg of KPV for 80 mg. What the fourth ingredient does and does not buy.

The identity test, what it cannot see, and how to read the line a certificate prints beside the purity number.

A walk through the most-cited stacks (BPC+TB, CJC+ipamorelin) — what’s been tested, what’s extrapolated, and what’s pure marketing.

Nine checks, the lot-matching step people skip, and a copy-paste request for vendors who have not published a certificate.

Six documented scam patterns, what analytical studies measured in vials bought online, and the check that catches each.

−20 °C for the powder, 2–8 °C once water goes in, one freeze only — the stability literature's actual answers.

Vial size, diluent, dose — concentration, draw volume and U-100 syringe units, with every step of the arithmetic shown.

A sourced peptide dosage chart. Every figure is what a published study or trial administered, with the citation…

Why some peptides last 30 minutes and others last 8 days. DPP-4 cleavage, albumin binding, and structural modifications.

The depot sites published protocols and approved labels name, why rotation is a pharmacokinetic control, and where the RUO limit falls.

Cost-per-mg by class, the 4 levers that drive price, cycle-cost examples, and why cheap peptides should prompt questions.

How reverse-phase HPLC measures peptide purity, why 95% vs. 99% matters, and what the 220 nm chromatogram is actually showing you.

Frozen vs. refrigerated vs. room-temperature stability windows. Lyophilized vial life, post-reconstitution life, and freeze-thaw cycle limits.

The arbitrary 50-residue threshold, the practical differences, and why the cutoff actually matters in formulation.

What 'peptides for sale' actually means, why the prices scatter so wildly, and the one request that separates a seller who tests from one who doesn't.

There is no retail counter for research peptides, and the reason is structural. What genuinely is available locally, and what isn't.

What changed when the FDA shifted several peptides out of 503A compounding eligibility — and what it meant for the grey market.

Ten vendors ranked on what each will actually show you: a lab report you can open, the lab named, lot matching and price per mg.

Not a ranking — the one email that sorts the market, and the six supplier checks in order of how much signal each carries.

What "third-party verified" means in 2026: HPLC purity floor, per-lot third-party COA, mass-spec identity, and the documentation chain that defines the category.

Which peptides sit on the WADA prohibited list, which categories they fall under, and the in-competition vs. out-of-competition distinction.

The FDA regulatory category, what RUO products can and can’t be sold for, and how the line is enforced.

The 50-amino-acid line that separates a peptide from a protein. Why the distinction matters for half-life, synthesis, and oral bioavailability.

0.9% benzyl alcohol bacteriostatic water for peptide reconstitution — USP grade, 28-day in-use stability.

Prescription, 503A compounding or the research-chemical market — the compound decides which route is open to you, not the seller.